Sana Biotechnology (SANA) is back in focus after announcing a collaboration with Mayo Clinic to advance SC451, its hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes, along with an equity investment component.

The Mayo Clinic collaboration and recent follow on offering have arrived alongside a sharp swing in sentiment, with a 22.8% 30 day share price return and a very large 1 year total shareholder return, even though the year to date share price return is still negative.

If this kind of clinical partnership has your attention, it could be a good time to see what else is moving in health related AI by checking out 35 healthcare AI stocks

With the share price still down year to date, despite a very large 1-year return and a recent rally, is Sana a misunderstood cell therapy play at a discount, or is the market already pricing in future growth?

Preferred Price to Book of 6.5x: Is It Justified?

Sana trades on a P/B of 6.5x, which sits close to a peer average of 6.7x but well above the broader US biotechs industry at 2.5x.

P/B compares the company’s market value with its net assets on the balance sheet. This can be a useful yardstick for pre revenue, loss making biotech names where earnings based ratios are less informative. For Sana, this means investors are paying a multiple of the company’s book value that is broadly aligned with a defined peer set, even though the company currently reports no revenue and a net loss of $244.166m.

Relative to peers on the same 6.7x benchmark, Sana’s 6.5x P/B looks roughly in line. This suggests investors are valuing each dollar of net assets at a similar level to that group. Against the wider US biotechs industry average of 2.5x, however, the current P/B is much richer, which points to the market assigning a higher value per dollar of equity than it does for the sector overall.

Result: Price to book of 6.5x (ABOUT RIGHT)

However, you still have to weigh funding needs for a pre revenue company, which is reporting a US$244.166m net loss, alongside clinical, regulatory and partnership execution risks.

Next Steps

Sentiment around Sana is clearly split. If this mix of risks and rewards has you thinking, it makes sense to look through the details yourself and form a view quickly, starting with the 1 key reward and 4 important warning signs

Looking for more investment ideas?

If you stop with just one stock on your radar, you risk missing out on other opportunities that better suit your goals and comfort with risk.

• Target resilient balance sheets and steady fundamentals by scanning companies in the solid balance sheet and fundamentals stocks screener (41 results).
• Hunt for quality at a potential discount by reviewing companies highlighted in the 63 high quality undervalued stocks.
• Lock in potential income ideas by checking out stocks featured in the 13 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.